{
    "clinical_study": {
        "@rank": "110958", 
        "arm_group": [
            {
                "arm_group_label": "ISIS-PTP1BRx", 
                "arm_group_type": "Experimental", 
                "description": "Weekly Dosing for 26 Weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Weekly Dosing for 26 Weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and efficacy of\n      ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo +\n      oral antidiabetic drug/s."
        }, 
        "brief_title": "Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes Mellitus", 
            "Obese"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) >/= 27 kg/m2\n\n          -  HbA1c between 7.5% and 10.5% (inclusive)\n\n          -  C-Peptide (fasting) greater than or equal to 500 pmol/L\n\n          -  On stable dose of metformin alone or in combination with a stable dose of\n             sulfonylurea for >/= 3 months prior to screening, and remain on stable dose\n             throughout the study\n\n          -  Agree to conduct home-based (fasted) blood glucose testing as directed\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities in medical history or physical exam\n\n          -  Serum creatinine > ULN at Screening\n\n          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or\n             AST > 1.5x ULN at Screening\n\n          -  History of renal transplantation or renal dialysis\n\n          -  GFR < 60 mL/min at Screening\n\n          -  History of diabetic ketoacidosis\n\n          -  History of greater than 3 episodes of severe hypoglycemia within 6 months of\n             screening\n\n          -  Allergy to sulfur containing drugs\n\n          -  Treatment with other drugs or medications not allowed per study specific Disallowed\n             Concomitant Medicines\n\n          -  Any other significant illness or condition that may interfere with the patient\n             participating or completing the study\n\n          -  Inability or unwillingness to comply with protocol or study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918865", 
            "org_study_id": "ISIS 404173-CS2"
        }, 
        "intervention": [
            {
                "arm_group_label": "ISIS-PTP1BRx", 
                "intervention_name": "ISIS-PTP1BRx", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ISIS-PTP1BRx", 
                    "Placebo"
                ], 
                "intervention_name": "daily OAD (metformin and/or sulfonylurea)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Type 2 Diabetes Mellitus", 
            "T2DM"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 2E1"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V1Y 3G8"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6J 1S3"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Etobicoke", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9R 4E1"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4G 3E8"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saskatoon", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S7K 3H3"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Centurion", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "0154"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mamelodi", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "0122"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "0001"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Elizabeth", 
                        "country": "South Africa", 
                        "state": "Korsten"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "state": "KwaZulu-Natal"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middelburg", 
                        "country": "South Africa", 
                        "state": "Mpumalanga"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limpopo", 
                        "country": "South Africa", 
                        "state": "Thabazimbi", 
                        "zip": "0380"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Western Cape", 
                        "zip": "7570"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "state": "Western Cape"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benoni", 
                        "country": "South Africa", 
                        "zip": "1500"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "zip": "9301"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "zip": "0184"
                    }, 
                    "name": "Isis Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea", 
        "overall_contact": {
            "email": "patients@isisph.com", 
            "last_name": "Isis Pharmaceuticals", 
            "phone": "+1-800-679-4747"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "South Africa: Medicines Control Council", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence, severity, dose-relationship of adverse effects, and changes in laboratory evaluations as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "38 weeks"
            }, 
            {
                "measure": "Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy", 
                "safety_issue": "No", 
                "time_frame": "27 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918865"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in FPG, weekly average SMPG, seven-point glucose profile, lipid profile, body weight, & BMI at Week 27 compared to Baseline as a measure of efficacy", 
            "safety_issue": "No", 
            "time_frame": "27 Weeks"
        }, 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}